Palliative/Supportive Care in End Stage Liver Disease

Richard K. Sterling, MD, MSc, FACP, FACG, AGAF, FAASLD

VCU Professor of Hepatology and Chief of Hepatology Assistant Chair for Research, Department of Medicine Associate Program Director, IM Resident Scholarship Medical Director, Viral Hepatitis and HIV Liver Clinic Virginia Commonwealth University Health System

Objectives

- Scope of the problem
- Definitions
- Factors in ESLD that lead to poor outcomes
- Current management
- Why palliative care needs to be incorporated into the management of ESLD

Scope of the problem

• Chronic liver disease (CLD) is common

- Viral hepatitis C (and B), NASH, Alcohol
- Increasing prevalence (NASH and Alcohol)
- Cirrhosis can develop in 20-25% in CLD
- Those with cirrhosis can progress to End Stage Liver Disease (ESLD)
 - Synthetic dysfunction: jaundice, coagulopathy, low albumin
 - Portal Hypertension: Ascites, varices, encephalopathy, SBP
 - Kidney dysfunction: Hyponatremia, AKI, HRS and CKD
 - Hepatocellular carcinoma (HCC)
- Once you develop hepatic decompensation, prognosis is poor
- The only long term treatment is liver transplantation

Hepatology consults at VCU: 3/21 to 7/21

- The majority of patients had underlying **alcohol-related liver disease followed by NASH and HCC**.
- The most common liver-related indications for admission were **ascites, HE, AKI, and portal hypertensive bleeding**. Of those admitted with ascites, 13% had SBP.
- The mean MELD at admission was 24.8. Importantly, 52% had a prior admission and of these 69% were re-admitted within 30 days of the prior discharge supporting the high burden of decompensated liver disease to our health system.
- Palliative care was consulted in only 10% and was higher in those with HCC (33%) than other diseases (<10%).

Palliative care is underutilized

Hepatology Inpatient Consults (N=155)		
Age (mean ± SD)	51±13	
Gender (male)	50%	
Race (White/Black)	75%/14%	
Liver Disease		
Alcohol	64%	
• NASH	16%	
• HCC	10%	
Indication for admission		
Ascites	71%	
• HE	64%	
• AKI	52%	
• PHT bleeding	30%	
Prior admission	52%	
Prior admission ≤ 30 days	69%	
MELD (mean ± SD)	24.8 ± 6.6	
Palliative care consult	10%	

Hospital readmissions at VCU

Between 2/10/17 and 5/10/20

 423 re-admissions among 235 patients (range 1-10 readmissions) within 30 days of the initial admission

Hospital Readmi	ssions
Age (mean ± SD)	56 ± 11
Gender (male)	63%
Race (White/Black)	65%/30%
Non-Hispanic	97%
Disease Etiology	
Alcohol	39%
HCV	14%
NASH	14%
Alcohol + HCV	17%
Comorbid diseases	
CKD	20%
DM	28%
HTN	47%
DL	15%
CAD	13%
НСС	17%
Depression	18%
AUD (current)	21%
MELD	22.8 ± 7.6

Liver Transplantation at VCU 2017-2020

Liver Transplants at VCU	2017	2018	2019	2020
Number	85	79	87	135
Age (years); median (IQR)	60 (46-67)	60 (46-67)	55 (34-67)	56 (36-67)
Gender (% male)	78	76	63	64
Race (% White/Black/other)	70/22/8	68/19/13	63/27/10	75/18/7
Disease etiology	<mark>8</mark> /3/17/8/30	24/13/19/4/1	24/7/25/6/	<mark>38</mark> /6/19/4/5
(% AUD/HCV/NASH/AUD+HCV/HCC)		5	5	
MELD at transplant; median (IQR)	28 (20-35)	29 (22-26)	26 (19-40)	27 (16-39)

Symptom and care burden often overlooked

- Reduced quality of life (QOL) (almost universal)
- Fatigue (52-86%)
- Depression (10-64%)
- Sleep disturbance (26-77%)
- Chronic pain (30-77%)
- Muscle cramps (56-68%)
- Frailty (17-43%)
- Sarcopenia (30-70%)
- Increased care giver burden

Not captured by MELD and Child class scores



46 (48.9)

44 (46.8)

43 (45.7)

43 (45.7)

41 (43.6)

40 (42.6)

39 (41.5)

36 (38.3)

34 (36.2)

33 (35.1)

32 (34.0)

32 (34.0)

30 (31.9)

26 (27.7)

25 (26.6)

13 (13.8)

12 (12.8)

Symptom Assessment

Variable	Patients n (%)	Numbness/tingling in
Pain	89 (94.7)	hands and feet
Lack of energy	87 (92.6)	Shortness of breath
Feeling drowsy	74 (78.7)	Change in the way
Difficulty sleeping	71 (75.5)	food tastes
Difficulty	66 (70.2)	Feeling nervous
concentrating		Dizziness
Lack of appetite	63 (67.0)	Cough
Feeling irritable	63 (67.0)	Diarrhea
Itching	62 (66.0)	Changes in skin
Dry mouth	61 (64.9)	I don't look like myself
Worrying	56 (59.6)	Constipation
Nausea	55 (58.5)	Problems with
Problems with	55 (58.5)	urination
sexual interest or		Sweats
activity		Vomiting
Swelling of arms	54 (57.5)	Difficulty swallowing
or legs		Weight loss
Feeling bloated	52 (55.3)	Hair loss
Feeling sad	50 (53.2)	Mouth sores

Hansen L, et al Gastroenterol Nurs 2016

© 2019 AMERICAN ASSOCIATION FOR THE STUDY OF LIVER DISEASES WWW.AASLD.ORG

Factors that affect the clinical picture in ESLD

Cirrhosis related	Physical inactivity	Organizational	Other
 Synthetic dysfunction Portal hypertension Fluid retention Ascites Cognitive dysfunction Encephalopathy Increased ammonia Anabolic resistance Etiology of liver disease HCC Edema Overall catabolic state Oxidative stress 	 Muscle disuse Cardiovascular deconditioning Frailty Sarcopenia Weakness 	 Delayed diagnosis Social determinants of health Lack of resources Confusion of responsibility Distance to liver center Insurance coverage Financial Care giver burden 	 Systemic inflammation Metabolic dysregulation Insulin resistance Endocrine dysfunction Age-related conditions Reduced testosterone Malnutrition Microbiome

Definitions

- Malnutrition
 - Imbalance (deficiency or excess) of nutrients and affect tissue body/form or function
- Frailty
 - Clinical state of decreased physiologic reserve
 - Physical frailty: impaired muscle contractile function that leads to decreased physical function, performance, and disability
- Sarcopenia
 - Progressive skeletal muscle


Malnutrition in ESLD

• Poor po intake

- Early satiety
- Nausea and vomiting
- Dysgeusia
- Unpalatable diet (low Na)
- Water restriction

• Defects in absorption/increased loss


- Fat soluble vitamins, fatty acids, zinc
- Bacterial overgrowth
- Na/K/Mg loss with diuretics
- NPO for procedures



P Tandon et al. J of Hep 2021;75:S147-162

Tools to assess frailty and sarcopenia

Frailty	Sarcopenia
Clinical frailty score (1-9)	Total skeletal muscle area at L3 normalized to height (Skeletal muscle index, SMI)
Karnofsky Performance Status (0-100)	DEXA
Liver Frailty Index (0-5)	Psoas muscle index
6 minute walk	Bioelectrical impedance analysis (BEI)
Grip strength	Anthropomorphic (mid-arm circumference, triceps skin fold thickness)



P Tandon et al. J of Hep 2021;75:S147-162

Current management of ESLD

• PCP \rightarrow local GI \rightarrow Hepatology/Transplant center


• Hepatology manages complications of liver disease

Some get evaluated for transplant (and some don't)

• Care of other symptoms get referred back to PCP



Across the Trajectory of Liver Disease:




Palliative (Supportive) Care in ESLD

- An approach that improves the quality of life of patients and their families who are facing problems associated with lifethreatening illness
- Ideally suited to help assess and care for those with systemic illness such as ESLD
- Provide holistic care to both patients and caregivers
- Focus on symptom management, goals of care discussions, advanced care planning, care giver burden
- Improve QOL, lower health care costs by preventing ER visits and readmissions, improve communications



Spectrum of Services for People with Advanced Liver Disease



Move PC consult to earlier In the disease




Palliative Care vs. Hospice

Palliative Care


- Receive medical treatment & palliative care concurrently
- Delivery of appropriate supportive interventions and consultations
- Coordination of care
- Collaboration with referring physician
- Goals of care/care preferences
- Help in navigating the healthcare system
- Facilitate transition to alternative care settings



- Life expectancy of six months or less
- Prepares the patient and the patient's family for his/her death
- Help with practical tasks like bathing
- Usually delivered at home or in nursing home
- Primarily nurse led (is interdisciplinary)
- Symptom management







Adapted from Ferrell et al., 1991; Ferrell et al., 1996



Advance Care Planning (ACP)

Awareness of Prognosis and Future Health Events

> Clarification of Values and Health Goals


> > Establishing Care Preferences

Establishing a Surrogate Decision Maker**

Documentation

Hastings Center Guidelines for End of Life Care Billings et al. JAMA Int Med 2014

Advance Care Planning



Hepatology 2018;67:2025-2040



Domains of Palliative Care: A perfect fit for ESLD




Adapted from National Consensus Project, 2018

Palliative Care in ESLD: AGA Best Practice

Table 1: AGA Best Practice Advice on PC in ESLD (adapted from Tandon et al) Care with PC principles should be provided to any patient with ESLD, irrespective of LT 1 candidacy and based on needs instead of prognosis. PC may be provided by health care providers from any specialty within any healthcare 2 setting. 3 Providers caring for those with ESLD should assess for the severity of symptoms within physical, psychosocial, social, and spiritual domains. Excellence in communications in goals of care, advanced care planning, and cultivating 4 prognostic awareness with patients and caregivers. Care in those with ESLD should include assessment of caregiver support and needs. 5 Prognosis should be evaluated during both routine visits and during sentinel events. 6 Goals of care discussions should be repeated at hospital admissions, when new complications develop, before the initiation of life saving therapies, before surgeries, and after LT eligibility.

- 8 Providers should optimize efficiencies in PC delivery including billing codes for services provided, surveys performed by ancillary staff, and multidisciplinary teams.
- 9 Healthcare teams should develop triggers and pathways for PC referrals in those with ESLD.
- **10** Timely referral to hospice for those with comfort-oriented goals and prognosis less than 6 months.

Integrating palliative care into ESLD management



Integrated team approach to palliative/supportive care in ESLD




Conclusions

- Liver disease is **common**.
- 20-30% will progress to cirrhosis and many progress to ESLD.
- In addition to complications of cirrhosis (synthetic and PHT), ESLD has frailty, sarcopenia and significant symptoms that impact QOL and care giver burden.
- Current care models (hepatologists) are ill equipped (and trained) to deal with these issues.
- This lead to **frequent ER visits and hospitalization**, increased \$\$.
- Palliative/supportive care is an ideal solution to improve patient care and QOL, care giver burden, and reduce health care costs.

Discovery Comes to the Prepared Mind



Thank you for your attention



804-828-9034 <u>Richard.Sterling@vcuhealth.org</u> **RichSterlingMD**